Back to top
more

Ocular Therapeutix (OCUL)

(Delayed Data from NSDQ)

$7.60 USD

7.60
2,612,399

+0.44 (6.15%)

Updated Jul 11, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

by Kinjel Shah

Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.

Benjamin Rains headshot

Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening

by Benjamin Rains

We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.90% and -1.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 2.17% and -23.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Ocular Therapeutix

by Zacks Equity Research

Ocular Therapeutix, Inc. (OCUL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

by Zacks Equity Research

The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

Implied Volatility Surging for Ocular (OCUL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.

Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

by Zacks Equity Research

Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

Options Traders Expect Huge Moves in Ocular (OCUL) Stock

by Zacks Equity Research

Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.

Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -7.14% and 10.31%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recro Pharma Falls as FDA Denies Approval to Pain Candidate

by Zacks Equity Research

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

by Zacks Equity Research

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock

by Zacks Equity Research

Ocular Therapeutix (OCUL) needs investors to pay close attention to the stock based on moves in the options market lately.

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -5.56% and 10.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0.00% and 85.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?